Illumina's genomic sequencing technology enjoys extensive citations in industry publications, and customer workflows have been developed around its systems that need to be repeated consistently.

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

Illumina's divestiture of GRAIL boosts financials, while strong gross margins and DNA sequencing growth drive potential. See ...

Healthcare - MedLife, the largest private healthcare network in Romania, has announced the acquisition of the advanced ...

In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...

Illumina said it has installed 469 NovaSeq X sequencing systems from its launch soon ... developed spatial biology system, which did not occur (Illumina expanded into single-cell ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

UofL Health’s Brown Cancer Center recently became the first facility in the US to offer its patients access to an FDA ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Thaysen described the company’s high-end sequencers, the NovaSeq X series, as integral to its growth; he expects revenue to reach high-single-digit percent growth by 2027.